JP3586471B2 - Torasemide-containing pharmaceutical composition - Google Patents
Torasemide-containing pharmaceutical composition Download PDFInfo
- Publication number
- JP3586471B2 JP3586471B2 JP18182091A JP18182091A JP3586471B2 JP 3586471 B2 JP3586471 B2 JP 3586471B2 JP 18182091 A JP18182091 A JP 18182091A JP 18182091 A JP18182091 A JP 18182091A JP 3586471 B2 JP3586471 B2 JP 3586471B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- weight
- torasemide
- pharmaceutical composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【０００１】
【産業上の利用分野】
本発明は、高血圧、浮腫の予防・治療剤、利尿剤などとして有用なトラセミド含有医薬組成物に関する。
【０００２】
【従来の技術・発明が解決しようとする課題】
トラセミド〔化学名、１−イソプロピル−３−（４−ｍ−トルイジノ−３−ピリジル）スルホニル〕ウレア〕は高血圧症治療用の利尿剤などとして有用である。トラセミドを含有する経口投与製剤としては、主薬に例えば糖、デンプン、デンプン誘導体、セルロース、セルロース誘導体、離型剤、抗粘着剤などの一般的助剤を加え、常法で製剤化することが知られており、例えば乳糖、トウモロコシデンプン、二酸化珪素、ステアリン酸マグネシウムを配合した錠剤として投与されている（特開昭６２−４５５７６号公開特許公報）。
【０００３】
一方、特に長期間保存した場合におけるトラセミド自体の保存安定性の改善、吸湿による製剤外観の変化の改善およびトラセミドの消化管からの吸収性がより一層改善され、バイオアベイラビリティーの優れた医薬製剤の出現が望まれている。従って、本発明は従来技術によるこのような問題点を解決し、優れたトラセミドを含有する経口投与用製剤を提供することを課題とする。
【０００４】
【課題を解決するための手段】
本発明者らは上記課題を解決するため、一般的な結合剤、崩壊剤、賦形剤、分散剤、溶解助剤等多数の成分中から特定成分の選択、組合せ、配合割合、溶出率、崩壊度、主薬安定性、主薬の吸収性等について広く検討した結果、トラセミド、ヒドロキシプロピルセルロースおよびクロスカルメロースナトリウムを含有する組成物、さらには乳糖または／および結晶セルロース等の賦形剤およびステアリン酸マグネシウムなどの滑沢剤を選択組合せた組成物、さらにまたこれらを一定比率で含有した医薬組成物が、いずれも経口投与用製剤として優れた特性を有することを見出し、本発明を完成するに至った。
【０００５】
即ち、本発明はトラセミド、ヒドロキシプロピルセルロースおよびクロスカルメロースナトリウムを含有した医薬組成物に関するものであり、特に好適にはトラセミド０．１〜２０部（以下重量部）、ヒドロキシプロピルセルロース１〜１０部、クロスカルメロースナトリウム１〜２０部を含有した医薬組成物に関するものである。
【０００６】
本発明において、トラセミドとしては、好適には例えば融点１６３〜１６４℃の白色結晶、融点１６９℃の柱状晶、融点１６２℃の葉状晶のものが使用される。トラセミドの製法としては特開昭５０−１４２５７１号、特開昭６２−４５５７６号の各公報等に記載の方法が例示される。トラセミドの塩としては薬理学的に許容され得るものであれば特に制限されず、例えば酢酸、コハク酸、マレイン酸、フマール酸、リンゴ酸、酒石酸、メタンスルホン酸等の有機酸との塩、塩酸、臭化水素酸、リン酸、硫酸等の無機酸との塩が例示される。
【０００７】
本発明では結合剤としてヒドロキシプロピルセルロースが選択され、特に高置換度のものが好ましい。このような高置換度ヒドロキシプロピルセルロースにおける置換度はヒドロキシプロポキシル基の含量（％）として、通常５０〜８０％、好ましくは６０〜７０％である。具体的にはヒドロキシプロピルセルロース（薬局方品）を用いる。
【０００８】
本発明の医薬組成物には、さらに賦形剤、滑沢剤などを配合してもよく、賦形剤としては、乳糖、結晶セルロースなどが好適に使用され、滑沢剤としては、ステアリン酸マグネシウムなどが好適に使用される。
【０００９】
本発明の医薬組成物における各成分の配合割合は、通常トラセミド０．１〜２０部（以下重量部）、好ましくは０．５〜１５部、さらに好ましくは１〜１０部、ヒドロキシプロピルセルロース１〜１０部、好ましくは２〜５部、クロスカルメロースナトリウム１〜２０部、好ましくは３〜１５部、さらに好ましくは５〜１０部である。本発明の医薬組成物に配合される他の成分の配合量は、賦形剤１０〜１５０部、好ましくは７０〜１４０部、さらに好ましくは１００〜１３０部、滑沢剤０．１〜５部、好ましくは０．２〜２部、さらに好ましくは０．５〜１．５部である。
【００１０】
本発明の医薬組成物は、高血圧、浮腫の予防・治療剤、利尿剤等として、好適には経口投与される。
本発明の医薬組成物は常法により各成分を混合し、散剤、細粒剤、顆粒剤、錠剤として製剤化される。
【００１１】
本発明の医薬組成物の投与量は、患者の性別、体重、年令、症状などに応じて変動するが、一般に成人では１日量としてトラセミドとして１〜３０ｍｇ程度であり、これを１日１〜数回に分けて投与する。
【００１２】
【実施例】
以下、本発明を具体的に説明するため、実施例および実験例を挙げるが、本発明はこれらによって何ら限定されるものではない。
【００１３】
実施例１
トラセミド４０ｇを乳糖１０６４ｇ、ヒドロキシプロピルセルロース（ヒドロキシプロポキシル基含量６２％）３２ｇ、クロスカルメロースナトリウム２４ｇと混合し、水で造粒し、乾燥後に篩過した。このもの４６６ｇにクロスカルメロースナトリウム１２．９ｇおよびステアリン酸マグネシウム３．２ｇを混合し、常法により打錠した。この操作により、１錠当たりトラセミド４ｍｇを含む錠剤約２３００錠を調製した。
【００１４】
実施例２
乳糖の代わりに結晶セルロースを用いて、実施例１に準じて錠剤を調製した。
【００１５】
実験例１
実施例１に準じて表１の組成からなる６種の製剤を調製した。なお、表中Ｎｏ． １は本発明の実施例、Ｎｏ． ２以降は比較例を示す。
【００１６】
【表１】
各組成物の崩壊時間、溶出率（３０分間）を、第１１改正日本薬局方の溶出試験に基づいて３７℃、５００ｍｌの条件下に調べた結果は、表２に示すとおりである。
【００１８】
【表２】
各組成物を４０℃、７５％相対湿度の条件下で１４日間放置し、外観、硬度、重量変化を調べた結果を表３〜５で示す。
【００２０】
【表３】
【表４】
【表５】
各組成物を６０℃で１ヶ月保存後に、類縁物質含量を調べた結果は表６のとおり。
【００２４】
【表６】
実験例２
本発明組成物（Ｎｏ． １）をトラセミドとして４ｍｇ、イヌ（体重８〜１２ｋｇ、例数６）に経口投与したところ、２４時間目までのトラセミドの血中濃度曲線下面積は４０．５±７．８（μｇ／ｍｌ・ｈｒ） であった。
【００２６】
【発明の効果】
以上説明したように、本発明のトラセミド含有医薬組成物は、トラセミドまたはその塩を主薬とし、ヒドロキシプロピルセルロースおよびクロスカルメロースナトリウムを選択することによって、トラセミド自体の保存安定性、吸湿による製剤の外観の変化、トラセミドの吸収性ひいてはバイオアベイラビリティー等が改善されるという効果を有するものである。[0001]
[Industrial applications]
The present invention relates to a toracemide-containing pharmaceutical composition useful as an agent for preventing or treating hypertension and edema, a diuretic, and the like.
[0002]
[Problems to be solved by the prior art / invention]
Toracemide [chemical name, 1-isopropyl-3- (4-m-toluidino-3-pyridyl) sulfonyl] urea] is useful as a diuretic for the treatment of hypertension. As an oral administration preparation containing torasemide, it is known that a common drug such as sugar, starch, a starch derivative, cellulose, a cellulose derivative, a release agent, an anti-adhesive agent, etc. is added to the main drug, and the formulation is made in a conventional manner. For example, it is administered as a tablet containing lactose, corn starch, silicon dioxide, and magnesium stearate (JP-A-62-45576).
[0003]
On the other hand, especially when stored for a long period of time, the storage stability of toracemide itself is improved, the change in the appearance of the formulation due to moisture absorption and the absorption of torasemide from the gastrointestinal tract are further improved, and a pharmaceutical preparation with excellent bioavailability is obtained. Appearance is desired. Therefore, an object of the present invention is to solve the above-mentioned problems caused by the prior art and to provide an excellent oral administration preparation containing torasemide.
[0004]
[Means for Solving the Problems]
The present inventors, in order to solve the above problems, general binders, disintegrants, excipients, dispersants, selection of specific components from a number of components such as dissolution aid, combination, blending ratio, dissolution rate, As a result of extensive studies on the degree of disintegration, the stability of the active ingredient, the absorption of the active ingredient, etc., a composition containing torasemide, hydroxypropylcellulose and croscarmellose sodium, and also excipients such as lactose or / and crystalline cellulose and stearic acid It has been found that a composition in which a lubricant such as magnesium is selectively combined, and a pharmaceutical composition containing these in a fixed ratio, all have excellent properties as a preparation for oral administration, and have completed the present invention. Was.
[0005]
That is, the present invention is torasemide, relates to pharmaceutical compositions containing hydroxypropyl cellulose and croscarmellose sodium, particularly preferably torasemide 0.1-20 parts (by weight or less parts), hydroxycarboxylic cellulose 1 The present invention relates to a pharmaceutical composition containing 10 parts of croscarmellose sodium and 1 to 20 parts.
[0006]
In the present invention, as the torasemide, for example, white crystals having a melting point of 163 to 164 ° C., columnar crystals having a melting point of 169 ° C., and leaf crystals having a melting point of 162 ° C. are preferably used. JP 50-142571 as preparation of torasemide, the method described in the Publication of JP 62-45576 are exemplified. The toracemide salt is not particularly limited as long as it is pharmacologically acceptable, and examples thereof include salts with organic acids such as acetic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, methanesulfonic acid, and hydrochloric acid. And salts with inorganic acids such as hydrobromic acid, phosphoric acid, and sulfuric acid.
[0007]
In the present invention hydroxypropylcellulose is selected as binding agent, is not preferable particularly high degree of substitution. As content of such substitution degree of the high-substituted hydroxypropylcellulose hydroxypropoxyl group (%) 50 to 80% usually, and preferably 60 to 70%. Specifically, hydroxypropyl cellulose (pharmacopoeial product) is used.
[0008]
The pharmaceutical composition of the present invention may further contain excipients, lubricants and the like, and as the excipient, lactose, crystalline cellulose and the like are suitably used, and as the lubricant, stearic acid is used. Magnesium and the like are preferably used.
[0009]
The compounding ratio of each component in the pharmaceutical composition of the present invention is generally from 0.1 to 20 parts (hereinafter referred to as “parts by weight”), preferably from 0.5 to 15 parts, more preferably from 1 to 10 parts, and 10 parts, preferably 2 to 5 parts, 1 to 20 parts of croscarmellose sodium, preferably 3 to 15 parts, more preferably 5 to 10 parts. The amount of other components to be blended in the pharmaceutical composition of the present invention is 10 to 150 parts of an excipient, preferably 70 to 140 parts, more preferably 100 to 130 parts, and 0.1 to 5 parts of a lubricant. , Preferably 0.2 to 2 parts, more preferably 0.5 to 1.5 parts.
[0010]
The pharmaceutical composition of the present invention is preferably orally administered as an agent for preventing or treating hypertension and edema, a diuretic, and the like.
The pharmaceutical composition of the present invention is prepared as a powder, fine granule, granule or tablet by mixing the respective components by a conventional method.
[0011]
The dosage of the pharmaceutical composition of the present invention varies depending on the sex, body weight, age, symptoms, etc. of the patient. In general, the daily dose for an adult is about 1 to 30 mg as torasemide per day, ~ Divided into several doses.
[0012]
【Example】
EXAMPLES Hereinafter, examples and experimental examples will be given in order to specifically describe the present invention, but the present invention is not limited thereto.
[0013]
Example 1
40 g of torasemide was mixed with 1064 g of lactose, 32 g of hydroxypropylcellulose (hydroxypropoxyl group content 62%) and 24 g of croscarmellose sodium, granulated with water, dried and sieved. To 466 g of the mixture were mixed 12.9 g of croscarmellose sodium and 3.2 g of magnesium stearate, and the mixture was tableted by a conventional method. By this operation, about 2300 tablets containing 4 mg of torasemide per tablet were prepared.
[0014]
Example 2
Tablets were prepared according to Example 1 using microcrystalline cellulose instead of lactose.
[0015]
Experimental example 1
According to Example 1, six formulations having the compositions shown in Table 1 were prepared. In the table, No. No. 1 is an embodiment of the present invention. Comparative examples 2 and thereafter show comparative examples.
[0016]
[Table 1]
The disintegration time and dissolution rate (30 minutes) of each composition were examined under the conditions of 37 ° C. and 500 ml based on the dissolution test of the 11th Revised Japanese Pharmacopoeia, and the results are as shown in Table 2.
[0018]
[Table 2]
Each composition was allowed to stand for 14 days under conditions of 40 ° C. and 75% relative humidity, and the results of examining the appearance, hardness, and weight change are shown in Tables 3 to 5.
[0020]
[Table 3]
[Table 4]
[Table 5]
After storing each composition at 60 ° C. for one month, the content of related substances was examined, as shown in Table 6.
[0024]
[Table 6]
Experimental example 2
When the composition of the present invention (No. 1) was orally administered to a dog (body weight: 8 to 12 kg, number of cases: 6) as torasemide, the area under the blood concentration curve of torasemide by 24 hours was 40.5 ± 7. 0.8 (μg / ml · hr).
[0026]
【The invention's effect】
As described above, the torsemide-containing pharmaceutical composition of the present invention is characterized in that toracemide or a salt thereof is used as the main drug and hydroxypropylcellulose and croscarmellose sodium are selected, whereby the storage stability of toracemide itself and the appearance of the formulation due to moisture absorption are obtained. And the effect of improving the absorbability of torasemide and, consequently, the bioavailability and the like.
Claims (3)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18182091A JP3586471B2 (en) | 1991-06-25 | 1991-06-25 | Torasemide-containing pharmaceutical composition |
| PCT/EP1992/001437 WO1993000097A1 (en) | 1991-06-25 | 1992-06-25 | Pharmaceutical preparations containing torasemid |
| EP92913781A EP0591363A1 (en) | 1991-06-25 | 1992-06-25 | Pharmaceutical preparations containing torasemid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18182091A JP3586471B2 (en) | 1991-06-25 | 1991-06-25 | Torasemide-containing pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05952A JPH05952A (en) | 1993-01-08 |
| JP3586471B2 true JP3586471B2 (en) | 2004-11-10 |
Family
ID=16107395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18182091A Expired - Lifetime JP3586471B2 (en) | 1991-06-25 | 1991-06-25 | Torasemide-containing pharmaceutical composition |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0591363A1 (en) |
| JP (1) | JP3586471B2 (en) |
| WO (1) | WO1993000097A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| EP1586314B1 (en) * | 1996-11-15 | 2011-03-30 | Ajinomoto Co., Inc. | Nateglinide tablet composition |
| DE10013289A1 (en) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Storage-stable formulations containing diuretic torasemide, are solids or semi-solids containing the active agent in non-crystalline form, e.g. as solid solution in vinyl pyrrolidone polymer matrix |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| EA007650B1 (en) * | 2002-01-16 | 2006-12-29 | Кова Ко., Лтд. | Medical composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US7109242B2 (en) | 2003-05-23 | 2006-09-19 | Kowa Company, Ltd. | Carboxylic compound and medicine comprising the same |
| ES2244324B1 (en) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | DIURETIC COMPOSITIONS OF PROLONGED RELEASE. |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| TWI471146B (en) | 2009-12-02 | 2015-02-01 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
| JP5617382B2 (en) | 2010-06-28 | 2014-11-05 | トヨタ紡織株式会社 | Intake manifold |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3529529A1 (en) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | METHOD FOR PRODUCING A STABLE MODIFICATION OF TORASEMIDE |
-
1991
- 1991-06-25 JP JP18182091A patent/JP3586471B2/en not_active Expired - Lifetime
-
1992
- 1992-06-25 WO PCT/EP1992/001437 patent/WO1993000097A1/en not_active Application Discontinuation
- 1992-06-25 EP EP92913781A patent/EP0591363A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05952A (en) | 1993-01-08 |
| EP0591363A1 (en) | 1994-04-13 |
| WO1993000097A1 (en) | 1993-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5837732B2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| JP3586471B2 (en) | Torasemide-containing pharmaceutical composition | |
| EP0889880B1 (en) | Eprosartan dihydrate and a process for its production and formulation | |
| EA029890B1 (en) | Pharmaceutical composition and pharmaceutical composition in oral dosage form based on dpp iv inhibitor | |
| JP2019505525A (en) | Pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof | |
| US20080125453A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
| AU780151B2 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
| KR100366130B1 (en) | Antihyperglycemic drugs | |
| TW509570B (en) | A stable cilansetron pharmaceutical preparation method for anti-racemization | |
| US4952410A (en) | Pharmaceutical products of moxonidine and hydrochlorothiazide | |
| JPH0678233B2 (en) | Pharmaceutical preparation having antihypertensive and cardioprotective effects | |
| US6420412B2 (en) | Eprosartan dihydate and a process for its production and formulation | |
| US6482417B2 (en) | Stable pharmaceutical formulation comprising torsemide modification II | |
| CN110613692A (en) | Topiroxostat tablet and preparation method thereof | |
| AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| US5091191A (en) | Pharmaceutical composition with improved dissolution property | |
| WO2000071117A1 (en) | Immediate release medicinal compositions for oral use | |
| JPH08325142A (en) | Isopropamide iodide-containing formulation | |
| JPH02211A (en) | Pharmacological composition and production thereof | |
| JPH0737383B2 (en) | Solid formulation containing gastric acid secretion inhibitor | |
| US20080118555A1 (en) | Stable pharmaceutical composition containing desloratadine | |
| JPS6023326A (en) | Peptide-containing drug preparation for oral administration | |
| JPH09249563A (en) | Tizanidin-containing composition | |
| KR910004481B1 (en) | Preparation for improved dissdution | |
| CN114762687A (en) | Premix of potassium ion competitive acid retarder and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040809 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070813 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 4 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090813 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 6 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 6 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100813 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110813 Year of fee payment: 7 |
|
| EXPY | Cancellation because of completion of term |